Michele Senni1, Rolf Wachter2,3, Klaus K Witte4, Ewa Straburzynska-Migaj5, Jan Belohlavek6, Candida Fonseca7, Christian Mueller8, Eva Lonn9, Arhit Chakrabarti10, Weibin Bao11, Adele Noe12, Heike Schwende12, Dmytro Butylin12, Domingo Pascual-Figal13. 1. Cardiology Division, Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy. 2. Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany. 3. Clinic for Cardiology and Pneumology, University Medicine Göttingen, Germany and German Cardiovascular Research Center, partner site Göttingen, Göttingen, Germany. 4. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK. 5. 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland. 6. General Teaching Hospital, Charles University in Prague, Prague, Czech Republic. 7. Heart Failure Unit, Internal Medicine Department, Hospital de São Francisco Xavier, CHLO, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. 8. University Hospital Basel, University of Basel, Basel, Switzerland. 9. McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. 10. Novartis Pharmaceuticals, Hyderabad, India. 11. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 12. Novartis Pharma AG, Basel, Switzerland. 13. Cardiology Department, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain.
Abstract
AIMS: Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM-HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER-HF and TRANSITION). However, data are lacking for the initiation of sacubitril/valsartan in newly diagnosed (de novo) HFrEF. Here, we assess the tolerability of initiating sacubitril/valsartan following ADHF in TRANSITION subgroups of patients with a de novo vs. prior diagnosis of HFrEF. METHODS AND RESULTS: TRANSITION randomised 1002 patients to pre- and post-discharge initiation of sacubitril/valsartan (analysis set n = 991, following exclusions for mis-randomisation). In this post-hoc analysis, tolerability to sacubitril/valsartan [proportion of patients achieving target dose (97/103 mg b.i.d.) at 10 weeks post-randomisation], adverse events (AEs) and serious AEs (SAEs) were compared in de novo (n = 286) and prior HFrEF (n = 705) subgroups. More de novo than prior HFrEF patients achieved target dose at Week 10 (56% vs. 45%; relative risk ratio 1.30, 95% confidence interval 1.12-1.52, P < 0.001), and fewer had SAEs and permanent treatment discontinuations. Initiation of sacubitril/valsartan did not prevent the concomitant initiation and up-titration of guideline-directed HF therapies. De novo patients showed faster and greater decreases in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin-T, and lower rates of HF and all-cause rehospitalisation vs. prior HFrEF. CONCLUSIONS: After ADHF, first-line initiation of sacubitril/valsartan in de novo HFrEF, alongside the initiation of other guideline-directed therapies, is feasible and is associated with a better risk-benefit profile than in patients with prior HFrEF. Early intervention with sacubitril/valsartan may be considered to delay disease progression in patients with de novo HFrEF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02661217.
RCT Entities:
AIMS: Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM-HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER-HF and TRANSITION). However, data are lacking for the initiation of sacubitril/valsartan in newly diagnosed (de novo) HFrEF. Here, we assess the tolerability of initiating sacubitril/valsartan following ADHF in TRANSITION subgroups of patients with a de novo vs. prior diagnosis of HFrEF. METHODS AND RESULTS: TRANSITION randomised 1002 patients to pre- and post-discharge initiation of sacubitril/valsartan (analysis set n = 991, following exclusions for mis-randomisation). In this post-hoc analysis, tolerability to sacubitril/valsartan [proportion of patients achieving target dose (97/103 mg b.i.d.) at 10 weeks post-randomisation], adverse events (AEs) and serious AEs (SAEs) were compared in de novo (n = 286) and prior HFrEF (n = 705) subgroups. More de novo than prior HFrEF patients achieved target dose at Week 10 (56% vs. 45%; relative risk ratio 1.30, 95% confidence interval 1.12-1.52, P < 0.001), and fewer had SAEs and permanent treatment discontinuations. Initiation of sacubitril/valsartan did not prevent the concomitant initiation and up-titration of guideline-directed HF therapies. De novo patients showed faster and greater decreases in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin-T, and lower rates of HF and all-cause rehospitalisation vs. prior HFrEF. CONCLUSIONS: After ADHF, first-line initiation of sacubitril/valsartan in de novo HFrEF, alongside the initiation of other guideline-directed therapies, is feasible and is associated with a better risk-benefit profile than in patients with prior HFrEF. Early intervention with sacubitril/valsartan may be considered to delay disease progression in patients with de novo HFrEF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02661217.
Authors: April F Mohanty; Emily B Levitan; Jordan B King; John A Dodson; Orly Vardeny; James Cook; Jennifer S Herrick; Tao He; Olga V Patterson; Patrick R Alba; Patricia A Russo; Engels N Obi; Michelle E Choi; James C Fang; Adam P Bress Journal: J Am Heart Assoc Date: 2021-10-06 Impact factor: 5.501
Authors: Suriya Prausmüller; Georg Spinka; Henrike Arfsten; Stefanie Stasek; Rene Rettl; Philipp Emanuel Bartko; Georg Goliasch; Guido Strunk; Julia Riebandt; Julia Mascherbauer; Diana Bonderman; Christian Hengstenberg; Martin Hülsmann; Noemi Pavo Journal: Cells Date: 2021-10-28 Impact factor: 6.600
Authors: Lorenzo Stretti; Dauphine Zippo; Andrew J S Coats; Markus S Anker; Stephan von Haehling; Marco Metra; Daniela Tomasoni Journal: ESC Heart Fail Date: 2021-12-16